Twist Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Twist Bioscience has a total shareholder equity of $590.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $732.8M and $142.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$311.14m |
| Equity | US$590.04m |
| Total liabilities | US$142.77m |
| Total assets | US$732.82m |
Recent financial health updates
We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate
Jan 22
Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans
Oct 05We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth
Jul 07Recent updates
Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Feb 27Twist Bioscience: Strong Performance In A Soft Market
Feb 07Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet
Jan 31We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate
Jan 22Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Dec 18Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans
Oct 05We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth
Jul 07Twist Biosciences collaborates with Enzolytics on monoclonal antibodies for viruses
Sep 16Twist Bioscience: DNA Synthesis Leader Appealing 'Picks And Shovels' Play
Sep 02Twist Bioscience: DNA Synthesis Leader Is Just Getting Started
Aug 08Twist Bioscience/ Biotia sequencing assay granted FDA nod to detect COVID variants
Aug 02Twist Biosciences to work with DNAnexus on sequencing-based diagnostic tests
Jul 13Twist Bioscience, Ildong team up to discover antibodies for cancer therapies
Jun 30Twist Bioscience: A First Take
May 26Financial Position Analysis
Short Term Liabilities: TWST's short term assets ($390.2M) exceed its short term liabilities ($65.2M).
Long Term Liabilities: TWST's short term assets ($390.2M) exceed its long term liabilities ($77.5M).
Debt to Equity History and Analysis
Debt Level: TWST is debt free.
Reducing Debt: TWST has no debt compared to 5 years ago when its debt to equity ratio was 7.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TWST has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TWST has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.7% each year